[
  {
    "ts": "2025-10-09T20:05:00+00:00",
    "headline": "Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025",
    "summary": "FOSTER CITY, Calif., October 09, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-release-third-quarter-200500018.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "88be33e9-d17e-35cb-ae81-868dad9210cb",
      "content": {
        "id": "88be33e9-d17e-35cb-ae81-868dad9210cb",
        "contentType": "STORY",
        "title": "Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025",
        "description": "",
        "summary": "FOSTER CITY, Calif., October 09, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update.",
        "pubDate": "2025-10-09T20:05:00Z",
        "displayTime": "2025-10-09T20:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a82119ec348cb973d40fdc7603ec6713",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d3yAUirm9FzOkbZSO85TPw--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a82119ec348cb973d40fdc7603ec6713.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Cp9L3wqIS_gEphKWg.Y6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a82119ec348cb973d40fdc7603ec6713.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-release-third-quarter-200500018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-release-third-quarter-200500018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T20:01:00+00:00",
    "headline": "Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update",
    "summary": "Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model Well capitalized with cash and marketable securities of $428.8 million SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage b",
    "url": "https://finance.yahoo.com/news/nurix-therapeutics-reports-third-quarter-200100331.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "12c1725f-eaf6-3174-a751-d2f81ba9ba4a",
      "content": {
        "id": "12c1725f-eaf6-3174-a751-d2f81ba9ba4a",
        "contentType": "STORY",
        "title": "Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update",
        "description": "",
        "summary": "Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model Well capitalized with cash and marketable securities of $428.8 million SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage b",
        "pubDate": "2025-10-09T20:01:00Z",
        "displayTime": "2025-10-09T20:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0",
          "originalWidth": 124,
          "originalHeight": 59,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bo1Kaht6Lnbt9HxUs8UQiw--~B/aD01OTt3PTEyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0.cf.webp",
              "width": 124,
              "height": 59,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d4ApEsx4wkV_auIuBRdN4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nurix-therapeutics-reports-third-quarter-200100331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nurix-therapeutics-reports-third-quarter-200100331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NRIX"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T12:00:00+00:00",
    "headline": "Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
    "summary": "SAN FRANCISCO, October 09, 2025--Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
    "url": "https://finance.yahoo.com/news/expedition-therapeutics-raises-165-million-120000819.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "1fc9b039-1af8-3743-8afa-5a844bc2979d",
      "content": {
        "id": "1fc9b039-1af8-3743-8afa-5a844bc2979d",
        "contentType": "STORY",
        "title": "Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
        "description": "",
        "summary": "SAN FRANCISCO, October 09, 2025--Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
        "pubDate": "2025-10-09T12:00:00Z",
        "displayTime": "2025-10-09T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/53214d389cde21f920b5d8117062fb16",
          "originalWidth": 480,
          "originalHeight": 264,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gpU2hmV3Z1Yf2bqH29UxMA--~B/aD0yNjQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/53214d389cde21f920b5d8117062fb16.cf.webp",
              "width": 480,
              "height": 264,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EZbQV0P.0sc1uyBHghrMEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/53214d389cde21f920b5d8117062fb16.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/expedition-therapeutics-raises-165-million-120000819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/expedition-therapeutics-raises-165-million-120000819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AKRO"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]